112 related articles for article (PubMed ID: 15075363)
21. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
22. Identification of viral macrophage inflammatory protein (vMIP)-II as a ligand for GPR5/XCR1.
Shan L; Qiao X; Oldham E; Catron D; Kaminski H; Lundell D; Zlotnik A; Gustafson E; Hedrick JA
Biochem Biophys Res Commun; 2000 Feb; 268(3):938-41. PubMed ID: 10679309
[TBL] [Abstract][Full Text] [Related]
23. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity.
Kim JH; Chen J; Majumder N; Lin H; Falo LD; You Z
Gene Ther; 2005 Oct; 12(20):1517-25. PubMed ID: 16052205
[TBL] [Abstract][Full Text] [Related]
24. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes.
Tunheim G; Schjetne KW; Fredriksen AB; Sandlie I; Bogen B
J Leukoc Biol; 2005 Mar; 77(3):303-10. PubMed ID: 15576418
[TBL] [Abstract][Full Text] [Related]
25. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.
Wareing MD; Lyon AB; Lu B; Gerard C; Sarawar SR
J Leukoc Biol; 2004 Oct; 76(4):886-95. PubMed ID: 15240757
[TBL] [Abstract][Full Text] [Related]
26. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.
Biragyn A; Surenhu M; Yang D; Ruffini PA; Haines BA; Klyushnenkova E; Oppenheim JJ; Kwak LW
J Immunol; 2001 Dec; 167(11):6644-53. PubMed ID: 11714836
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
28. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
Ren W; Strube R; Zhang X; Chen SY; Huang XF
Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
[TBL] [Abstract][Full Text] [Related]
29. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
30. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.
Deriy L; Ogawa H; Gao GP; Galili U
Cancer Gene Ther; 2005 Jun; 12(6):528-39. PubMed ID: 15818383
[TBL] [Abstract][Full Text] [Related]
31. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.
Westermann J; Nguyen-Hoai T; Baldenhofer G; Höpken UE; Lipp M; Dörken B; Pezzutto A
Cancer Gene Ther; 2007 Jun; 14(6):523-32. PubMed ID: 17384577
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
33. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
34. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.
Wang YS; Wang GQ; Wen YJ; Wang L; Chen XC; Chen P; Kan B; Li J; Huang C; Lu Y; Zhou Q; Xu N; Li D; Fan LY; Yi T; Wu HB; Wei YQ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6779-87. PubMed ID: 18006780
[TBL] [Abstract][Full Text] [Related]
35. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.
Chu Y; Xia M; Lin Y; Li A; Wang Y; Liu R; Xiong S
Cancer Gene Ther; 2006 May; 13(5):510-9. PubMed ID: 16341143
[TBL] [Abstract][Full Text] [Related]
36. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells.
Yoshikawa T; Okada N; Oda A; Matsuo K; Matsuo K; Kayamuro H; Ishii Y; Yoshinaga T; Akagi T; Akashi M; Nakagawa S
Vaccine; 2008 Mar; 26(10):1303-13. PubMed ID: 18255205
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
Avigan D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
[TBL] [Abstract][Full Text] [Related]
39. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
Brück J; Steitz J; Strand D; Tüting T
J Gene Med; 2005 May; 7(5):613-20. PubMed ID: 15580620
[TBL] [Abstract][Full Text] [Related]
40. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.
Chhabra A; Mehrotra S; Chakraborty NG; Mukherji B; Dorsky DI
Eur J Immunol; 2004 Oct; 34(10):2824-33. PubMed ID: 15368298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
